Copenhagen 2016 Registration Programme Exhibitor Information Virtual Exhibition Satellite Meetings Glaucoma Day 2016 Hotel Star Alliance
title

10 - 14 Sept. 2016, Bella Center, Copenhagen, Denmark

This Meeting has been awarded 27 CME credits

 

escrs app advert yo advert

Effect of energy levels and anti-inflammatory drops on macular thickness post YAG laser capsulotomy

Search Title by author or title

Session Details

Session Title: Presented Poster Session: PCO

Session Date/Time: Sunday 11/09/2016 | 09:30-11:00

Paper Time: 10:50

Venue: Poster Village: Pod 1

First Author: : N.Shah INDIA

Co Author(s): :    A. Braganza   A. Heda   P. Subbaiah        

Abstract Details

Purpose:

To assess the effect of varying energy levels and anti-inflammatory drops on change in macular thickness (MT) after Nd:YAG laser capsulotomy for posterior capsular opacification (PCO).

Setting:

tertiary eye care hospital

Methods:

Patients who underwent uneventful phacoemulsification with in the bag IOL implantation by the same surgeon were followed up for 6 months for PCO formation Nd:YAG laser capsulotomy was done and change in macular thickness was assessed by OCT caliper before and after 1 week of capsulotomy Based on energy used in epithelial and fibrous PCO, patients were divided into two groups Group-1 (0-50mJ) Group-2 (>50mJ) Anti-inflammatory drops 0.03% flurbiprofen and 0.1% nepafenac were randomly used in the 2 groups post YAG capsulotomy

Results:

Mean age of the patient 62.79 ± 13.9 years Mean UCVA & BCVA in Group-1 was 0.28 ± 0.20 & 0.05 ± 0.09 by LogMAR Mean UCVA & BCVA in Group-2 was 0.54 ± 0.94 & 0.07 ± 0.10 by LogMAR.In group 1,pre macular thickness was 205 ±19.08 which increased to 203.4 ± 28.44.In group 2 pre macular thickness was 211.8 ±19.54 which increased to 224.7 ± 27.68.So the mean macular thickness in group 1 and 2 was 1.61 and 12.9 respectively.

Conclusions:

The change in MT following Nd:YAG capsulotomy is significant when the total energy used is above 50mJ irrespective of the anti-inflammatory drops administered

Financial Disclosure:

NONE

Back to previous